India markets open in 8 hours 53 minutes
  • BSE SENSEX

    49,591.32
    -154.88 (-0.31%)
     
  • Nifty 50

    14,834.85
    -38.95 (-0.26%)
     
  • Dow

    33,800.60
    +297.00 (+0.89%)
     
  • Nasdaq

    13,900.19
    +70.89 (+0.51%)
     
  • BTC-INR

    4,485,425.50
    -4,767.00 (-0.11%)
     
  • CMC Crypto 200

    1,235.89
    +8.35 (+0.68%)
     
  • Hang Seng

    28,698.80
    -309.30 (-1.07%)
     
  • Nikkei

    29,768.06
    +59.06 (+0.20%)
     
  • EUR/INR

    88.9028
    +0.0430 (+0.05%)
     
  • GBP/INR

    102.3868
    -0.0112 (-0.01%)
     
  • AED/INR

    20.2980
    +0.0430 (+0.21%)
     
  • INR/JPY

    1.4647
    +0.0019 (+0.13%)
     
  • SGD/INR

    55.7130
    +0.0690 (+0.12%)
     

The Law Offices of Frank R. Cruz Announces Investigation of Athenex, Inc. (ATNX) on Behalf of Investors

·2-min read

The Law Offices of Frank R. Cruz announces an investigation of Athenex, Inc. ("Athenex" or the "Company") (NASDAQ: ATNX) on behalf of investors concerning the Company’s possible violations of federal securities laws.

If you are a shareholder who suffered a loss, click here to participate.

Athenex is a clinical stage biopharmaceutical company. Its main product candidate is an oral paclitaxel and encequidar for the treatment of metastatic breast cancer.

On September 1, 2020, the Company announced that the U.S. Food and Drug Administration ("FDA") accepted Athenex’s New Drug Application ("NDA") for oral paclitaxel and encequidar in metastatic breast cancer with priority review.

On March 1, 2021, before the market opened, Athenex disclosed receipt of a Complete Response Letter ("CRL") from the FDA stating that the NDA would not be approved in its current form. According to the CRL, "the FDA indicated its concern of safety risk to patients in terms of an increase in neutropenia-related sequalae on the Oral Paclitaxel arm compared to the IV paclitaxel arm." The Company stated that the "FDA also expressed concerns regarding the uncertainty over the results of the primary endpoint of objective response rate (ORR) at week 19 conducted by blinded independent centra review (BICR) [because] the BICR reconciliation and re-read process may have introduced unmeasured bias and influence on the BICR." As a result, the FDA had recommended that Athenex conduct additional clinical trials and employ certain risk mitigation strategies to improve toxicity.

On this news, the Company’s stock price fell $6.64, or 55%, to close at $5.46 per share on March 1, 2021, thereby injuring investors.

Follow us for updates on Twitter: twitter.com/FRC_LAW.

If you purchased Athenex securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Frank R. Cruz, of The Law Offices of Frank R. Cruz, 1999 Avenue of the Stars, Suite 1100, Los Angeles, California 90067 at 310-914-5007, by email to info@frankcruzlaw.com, or visit our website at www.frankcruzlaw.com. If you inquire by email please include your mailing address, telephone number, and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210303005989/en/

Contacts

The Law Offices of Frank R. Cruz, Los Angeles
Frank R. Cruz, 310-914-5007
fcruz@frankcruzlaw.com
www.frankcruzlaw.com